Article
An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.
All News
Article
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
Article
Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).
As goes SLE, bullous disease typically affects women, especially those of African descent.
Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.
Article
A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE).
Article
A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs.
Dr. John Cush
Tweet
Study of 130 patients with ITP (w/ 10 later Dx SLE (30 mos F/U). Risk factors for ITP developing SLE included young age (< 40yrs; OR 6.3), organ bleeding (OR 13.7), and ANA (≥ 1:160; OR 6.6) https://t.co/XSJdio2rR1 https://t.co/oCyFjJnxTX
Dr. John Cush
Tweet
Voclosporin Efficacy and Safety in Lupus Nephritis
An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.
https://t.co/LSjmRB2Zr3 https://t.co/z9MoJ0uRzz
Dr. John Cush
Tweet
ANA Increasing? Part of the NHANES survey, ANA (IIF on HEp-2 cells) was performed on 13,519 in 3 periods: 1988-1991, 1999-2004, and 2011-2012. ANA+ was
11% 1988-1991
11.4% 1999-2004
16.1% 2011-2012 (P <0.0001)
Meaning ~22.3, ~26.6, &~41.5 mil had +ANAs https://t.co/vWYJci3uDV https://t.co/SEIbrYRoRJ
Laurent ARNAUD
Tweet
✅ Probably one of my most important slides ⬇️
WHY IS MY #TREATMENT NOT WORKING (or not working enough) 😭 This is really a question we're dealing with everyday in #rheumatology when taking care of patients with #autoimmune and other rheumatic diseases 👍 https://t.co/osUPYSvuWf
Dr. John Cush
Tweet
Autoimmune Disease Augments Cardiovascular Risk
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
https://t.co/TtiH9ZBkR8 https://t.co/jVZBk8l4XD
Dr. John Cush
Tweet
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/lSvnAkRvxB https://t.co/i7ZORYyKHP
Donald Thomas, MD
Tweet
Learn how to manage lupus: 'The Lupus Encyclopedia: A Comprehensive Guide for Patients and Families' - on #BookBuzz - https://t.co/hvnoFRiabA
Dr. John Cush
Tweet
Chinese study of 215 Bx proven #SLE pts - all rx w/ IV CTX+steroids. Responders were given either AZA or leflunomide. Renal outcomes were same w/ LEF or AZA as maintenance. Flares (16% vs 18%), Time to flare (16 v 14 mos), AE, proteinuria https://t.co/Ad7Ec4OPco https://t.co/NoKAgiMKrK
Dr. John Cush
Tweet
Low Dose IL-2 Therapy in SLE
A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe SLE.
https://t.co/PNOp3Zdc8M https://t.co/B8DmUs5iuH
Dr. John Cush
Tweet
Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage. https://t.co/gbSn0ZcFEK https://t.co/qjOSNvkIPC
Dr. John Cush
Tweet
Worldwide there are 484,213 #SLE cases in 2017 (7MM), with 54% in the USA (259,474 cases), the rest in the EU and Japan. Next most prevalent was UK (62,852) followed by Italy. Spain has lowest prevalence of SLE https://t.co/anRCYwrLoM https://t.co/nHbLzC0mSd
Dr. John Cush
Tweet
Medicare study of 10,868 Hospitalized lupus pts. Looking at age groups. 30 d rehospitalization higher in young adult LE (36%) - 40% higher than those without LE, 85% higher older LE. Rehospitalization higher with Longer hosp stay & higher comorbidity. https://t.co/Ul91DX6H8r https://t.co/t3plpQQ8qn
Dr. John Cush
Tweet
Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU
Dr. John Cush
Tweet
Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage. https://t.co/Mxe53pCnEF https://t.co/BOspodqpSE
